奈达单抗治疗强直性脊柱炎患者的实际保留率、有效性和安全性:LIBRA注册后安全性研究的第一年结果。

IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Doklady Biochemistry and Biophysics Pub Date : 2024-08-28 DOI:10.1134/S1607672924701084
Sh. Erdes, V. I. Mazurov, I. Z. Gaydukova, O. N. Anoshenkova, I. B. Vinogradova, Yu. Yu. Grabovetskaya, S. Y. Davidian, N. A. Kiryukhina, O. E. Epifanova, L. V. Masneva, L. V. Menshikova, O. N. Mironenko, N. E. Nikulenkova, T. V. Povarova, A. N. Poliatika, R. R. Samigullina, A. E. Sizikov, I. N. Totrov, I. F. Umnova, J. V. Usacheva, A. L. Chudinov
{"title":"奈达单抗治疗强直性脊柱炎患者的实际保留率、有效性和安全性:LIBRA注册后安全性研究的第一年结果。","authors":"Sh. Erdes,&nbsp;V. I. Mazurov,&nbsp;I. Z. Gaydukova,&nbsp;O. N. Anoshenkova,&nbsp;I. B. Vinogradova,&nbsp;Yu. Yu. Grabovetskaya,&nbsp;S. Y. Davidian,&nbsp;N. A. Kiryukhina,&nbsp;O. E. Epifanova,&nbsp;L. V. Masneva,&nbsp;L. V. Menshikova,&nbsp;O. N. Mironenko,&nbsp;N. E. Nikulenkova,&nbsp;T. V. Povarova,&nbsp;A. N. Poliatika,&nbsp;R. R. Samigullina,&nbsp;A. E. Sizikov,&nbsp;I. N. Totrov,&nbsp;I. F. Umnova,&nbsp;J. V. Usacheva,&nbsp;A. L. Chudinov","doi":"10.1134/S1607672924701084","DOIUrl":null,"url":null,"abstract":"<p>Netakimab has shown high efficacy in controlled clinical trials in the treatment of AS patients. This article presents results of an observational study of netakimab using in routine clinical practice.</p><p>To evaluate retention rates and safety of netakimab in patients with AS in real-world clinical practice. Additionally, the efficacy of netakimab was evaluated at 1-year follow-up.</p><p>Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, and 52 weeks of therapy were collected within the study. Drug survival rate was calculated according to Kaplan–Meier analysis.</p><p>The study included 137 (93 men and 44 women) patients with AS. The average age of patients was 42.3 (11.9) years, 34.3% of patients had previously received therapy with bDMARD, mainly TNF inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% (95% CI, 85.4-95.7) of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; AEs, related to therapy according to the investigator’s opinion, were reported in 7 (5.1%) patients. Two patients stopped taking netakimab due to AEs (terminal ileitis and chronic colitis).</p><p>In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study\",\"authors\":\"Sh. Erdes,&nbsp;V. I. Mazurov,&nbsp;I. Z. Gaydukova,&nbsp;O. N. Anoshenkova,&nbsp;I. B. Vinogradova,&nbsp;Yu. Yu. Grabovetskaya,&nbsp;S. Y. Davidian,&nbsp;N. A. Kiryukhina,&nbsp;O. E. Epifanova,&nbsp;L. V. Masneva,&nbsp;L. V. Menshikova,&nbsp;O. N. Mironenko,&nbsp;N. E. Nikulenkova,&nbsp;T. V. Povarova,&nbsp;A. N. Poliatika,&nbsp;R. R. Samigullina,&nbsp;A. E. Sizikov,&nbsp;I. N. Totrov,&nbsp;I. F. Umnova,&nbsp;J. V. Usacheva,&nbsp;A. L. Chudinov\",\"doi\":\"10.1134/S1607672924701084\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Netakimab has shown high efficacy in controlled clinical trials in the treatment of AS patients. This article presents results of an observational study of netakimab using in routine clinical practice.</p><p>To evaluate retention rates and safety of netakimab in patients with AS in real-world clinical practice. Additionally, the efficacy of netakimab was evaluated at 1-year follow-up.</p><p>Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, and 52 weeks of therapy were collected within the study. Drug survival rate was calculated according to Kaplan–Meier analysis.</p><p>The study included 137 (93 men and 44 women) patients with AS. The average age of patients was 42.3 (11.9) years, 34.3% of patients had previously received therapy with bDMARD, mainly TNF inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% (95% CI, 85.4-95.7) of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; AEs, related to therapy according to the investigator’s opinion, were reported in 7 (5.1%) patients. Two patients stopped taking netakimab due to AEs (terminal ileitis and chronic colitis).</p><p>In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy.</p>\",\"PeriodicalId\":529,\"journal\":{\"name\":\"Doklady Biochemistry and Biophysics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Doklady Biochemistry and Biophysics\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://link.springer.com/article/10.1134/S1607672924701084\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Doklady Biochemistry and Biophysics","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1134/S1607672924701084","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

奈达单抗在治疗强直性脊柱炎患者的对照临床试验中显示出很高的疗效。本文介绍了在常规临床实践中使用奈达单抗的观察性研究结果:目的:评估在实际临床实践中使用奈达单抗治疗强直性脊柱炎患者的保留率和安全性。此外,还对奈达单抗在1年随访中的疗效进行了评估:2020 年 8 月至 2021 年 12 月期间,在俄罗斯联邦的 23 个中心招募患者参与研究。研究对象包括入组前已接受奈达单抗治疗的患者,因此首次就诊的临床和病史数据以回顾性方式录入,并在研究范围内收集治疗 12 周、24 周和 52 周的后续就诊数据。根据卡普兰-梅耶尔分析法计算药物存活率:研究纳入了 137 名(男性 93 名,女性 44 名)强直性脊柱炎患者。患者平均年龄为42.3(11.9)岁,34.3%的患者曾接受过bDMARD治疗,主要是TNF抑制剂。在分析期结束时(治疗 52 周),90.4%(95% CI,85.4-95.7)的患者继续接受奈达单抗治疗。在所有时间点,BASDAI和ASDAS-CRP的评分与基线相比均有统计学意义上的显著下降。患者对奈达单抗的耐受性良好;根据研究者的意见,7 例(5.1%)患者出现了与治疗相关的 AE。两名患者因不良反应(末端回肠炎和慢性结肠炎)而停止服用奈达单抗:在真实世界的临床实践中,奈达单抗的保留率很高,安全性良好,在第一年的治疗中疗效持续。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study

Netakimab has shown high efficacy in controlled clinical trials in the treatment of AS patients. This article presents results of an observational study of netakimab using in routine clinical practice.

To evaluate retention rates and safety of netakimab in patients with AS in real-world clinical practice. Additionally, the efficacy of netakimab was evaluated at 1-year follow-up.

Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, and 52 weeks of therapy were collected within the study. Drug survival rate was calculated according to Kaplan–Meier analysis.

The study included 137 (93 men and 44 women) patients with AS. The average age of patients was 42.3 (11.9) years, 34.3% of patients had previously received therapy with bDMARD, mainly TNF inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% (95% CI, 85.4-95.7) of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; AEs, related to therapy according to the investigator’s opinion, were reported in 7 (5.1%) patients. Two patients stopped taking netakimab due to AEs (terminal ileitis and chronic colitis).

In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Doklady Biochemistry and Biophysics
Doklady Biochemistry and Biophysics 生物-生化与分子生物学
CiteScore
1.60
自引率
12.50%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Doklady Biochemistry and Biophysics is a journal consisting of English translations of articles published in Russian in biochemistry and biophysics sections of the Russian-language journal Doklady Akademii Nauk. The journal''s goal is to publish the most significant new research in biochemistry and biophysics carried out in Russia today or in collaboration with Russian authors. The journal accepts only articles in the Russian language that are submitted or recommended by acting Russian or foreign members of the Russian Academy of Sciences. The journal does not accept direct submissions in English.
期刊最新文献
Transriptome Analysis of Peripheral Blood Monocytes in Chronic Obstructive Pulmonary Disease Patients. A Study of the Comparability of the Pharmacodynamic, Toxicological, and Pharmacokinetic Properties of the Reference Drug Pulmozyme® and the Biosimilar Drug Tigerase®. Effect of Bioplastic Material on Adhesion, Growth, and Proliferative Activity of Human Fibroblasts When Incubated in Solutions Mimic the Acidity of Wound an Acute and Chronic Inflammation. Effects of Overexpression of Specific Subunits SAYP, BAP170 of the Chromatin Remodeling Complex in Drosophila Melanogaster. Features of Brain Damage after Neutron Irradiation of the Head and Modification of the Damage by Lactoferrin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1